Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Immunomic Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
Immunomic Therapeutics

Immunomic Therapeutics

Series D

US-based Immunomic Therapeutics, Inc. develops vaccines for allergies and other health targets.

HQ
Rockville, MD, US
Founded
2005
Overview
Compare
Fundraising
Employees
Website

Founded in Rockville, United States, Immunomic Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to pioneering the development of vaccines using lysosomal associated membrane protein (LAMP) technology. The company's core mission is to create innovative vaccines for the treatment of allergies and other significant health targets. Their product pipeline includes ITI-1000 and ITI-1001 for Glioblastoma Multiforme and ITI-3000 for Merkel Cell Carcinoma, focusing on addressing critical unmet medical needs.

Immunomic Therapeutics has attracted notable investors and partnerships, contributing to its growth and development. The company has achieved significant milestones in advancing its clinical trials, particularly in the field of oncology. Its innovative approach has the potential to revolutionize vaccine development and impact patient outcomes positively. The overall impact of Immunomic Therapeutics is marked by its commitment to transforming the landscape of immunotherapy and providing new hope for patients with challenging health conditions.

Immunomic Therapeutics - Similar Companies

Immunome logo

Immunome

Inimmune logo

Inimmune

inimmune.com

Immune-Onc Therapeutics logo

Immune-Onc Therapeutics

immuneonc.com

AIM Immunotech logo

AIM Immunotech

aimimmuno.com

Immunophotonics logo

Immunophotonics

INmune Bio logo

INmune Bio

inmunebio.com

Imvax logo

Imvax

imvax.com

MimiVax logo

MimiVax

mimivax.com

Intrommune Therapeutics logo

Intrommune Therapeutics

intrommune.com

Immunitas Therapeutics logo

Immunitas Therapeutics

immunitastx.com

Agilvax logo

Agilvax

IM Therapeutics logo

IM Therapeutics

imtherapeutics.com

Imunon logo

Imunon

imunon.com

EpiVax Oncology logo

EpiVax Oncology

epivaxtx.com

ImmunGene logo

ImmunGene

Immunomic Therapeutics - Quick Facts

Who are Immunomic Therapeutics' competitors?

Companies similar to Immunomic Therapeutics include Immunome, Inimmune, Immune-Onc Therapeutics and AIM Immunotech.

When was Immunomic Therapeutics founded?

Immunomic Therapeutics was founded in 2005.

Where is Immunomic Therapeutics' headquarters located?

Immunomic Therapeutics' headquarters is located in Rockville, MD, US.

When was Immunomic Therapeutics' last funding round?

Immunomic Therapeutics' most recent funding round was for $61.3M (USD) in April 2020.

How much has Immunomic Therapeutics raised to-date?

As of Apr 23, 2020, Immunomic Therapeutics has raised a total of $75.4M (USD).

How many employees does Immunomic Therapeutics have?

Immunomic Therapeutics has 31 employees as of Feb 5, 2024.

Immunomic Therapeutics - Classification

Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Vaccines
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 13 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 8000Health Services
  • 2830Drugs
  • 8040Offices And Clinics Of Other Health Practitioners
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified